Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces the appointment of Professor Pierre Corvol as Chairman of its Scientific Advisory Board.
Pierre Corvol is a specialist of the renin-angiotensin system. He discovered the major role of this system in the regulation of arterial blood pressure. His works were at the origin of the treatment of cardiovascular diseases with inhibitors of the renin system.
The advisory board will be composed international scientific experts in the field of cardiology. It will provide recommendations for the research and development programs of Quantum Genomics and address in particular the question of relevant biomarkers for resistant hypertension and congestive heart failure
The other members will be announced in September 2014.
Pierre Corvol
Professor Emeritus at Collège de France
Honorary Director of Collège de France
Member of the Academy of Sciences
Member of the Academy of Medicine
Member of the American Academy of Arts and Sciences
Pierre Corvol, medical doctor, is Professor Emeritus at Collège de France and honorary director of Collège de France. He headed the high blood pressure service of the Broussais Hospital (1986 -1999) and was director of the Inserm unit of Vascular and renal endocrinology pathology (1982-2006). He was Professor at Collège de France (Chair of Experimental Medicine) from 1989 to 2012.
His research was focused on the study of hormonal mechanisms of regulating blood pressure. He established the crucial role of the renin - angiotensin - aldosterone system in the regulation of renal and cardiac function. The work of his team has contributed to the development of treatments commonly used to treat high blood pressure and cardiovascular diseases.
He conducted the first studies on the genetics of human hypertension. He recently worked on angiogenesis and the remodelling of the arterial wall in cardiovascular pathologies.
He is a member of the Academy of Sciences, the Academy of Medicine and the American Academy of Arts and Sciences. He has received numerous awards including the Ciba Award for Hypertension Research (1985) and the Grand Prix Inserm (2006). Main publications (from over 732): cloning of renin and angiotensin converting enzyme (Nature, 1982; PNAS, 1988); Molecular genetics of human hypertension (Cell, 1992); Functional consequences of inactivating mutations of the renin system in humans (Human Mol. Genetics, 2011 and 2013).
Pierre Corvol is appointed Chairman of the Scientific Advisory Board of Quantum Genomics for a period of 4 years.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.
Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).
Contacts
| Quantum Genomics Lionel Ségard CEO (+33) 1 60 13 76 80 | Quantum Genomics Marc Karako CFO - Investor relations (+33) 1 60 13 76 84 [email protected] | ACTUS Jean-Michel Marmillon Press relations (33) 1 53 67 07 80 [email protected] |
- SECURITY MASTER Key: yJueZ8lsZWyVy2+ckplpmWNqa2ZkxWKcm5aVxGpwk5eWbWlpnJqWbJSYZmxnmmlp
- Check this key: https://www.security-master-key.com.